AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
1 Waukegan Rd, North Chicago, IL 60064
Brief summary of the
materials and/or video content:
This video is a recording of an accepted abstract and poster that was planned for presentation at the 2020 PES Annual Meeting:
Individualized treatment decisions in girls with central precocious puberty (CPP) treated with leuprolide are important for girls starting treatment after age 7 years old or continuing treatment beyond a bone age of 12 years. Children who initiate treatment after age 7 years have improvements in predicted adult height (PAH) similar to those who initiate treatment at a younger age. Continued improvement in PAH is consistent with longer duration of treatment, suggesting that an absolute bone age (BA) limit to define end of treatment should not be used in subjects still growing well and not yet at mid-parental height. Range of increase in PAH after BA of 12 years was wide, consistent with the need to individualize treatment duration. Treatment should be individualized, and cessation of treatment should not be based on BA or chronological age (CA) alone.
Have questions? Please contact:
Director, U.S. Public Affairs
Enter the MAP Spotlight Raffle